These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 1968506)

  • 21. Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes.
    Willey RL; Maldarelli F; Martin MA; Strebel K
    J Virol; 1992 Jan; 66(1):226-34. PubMed ID: 1727486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA; Schwartz DH; Fabry JA; Lieberman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fusion of the upstream vpu sequences to the env of simian human immunodeficiency virus (SHIV(KU-1bMC33)) results in the synthesis of two envelope precursor proteins, increased numbers of virus particles associated with the cell surface and is pathogenic for pig-tailed macaques.
    Hout DR; Gomez ML; Pacyniak E; Mulcahy ER; Gomez LM; Jackson M; Flick M; Fegley B; McCormick C; Wisdom BJ; Culley N; Pinson DM; Powers M; Wong SW; Stephens EB
    Virology; 2004 May; 323(1):91-107. PubMed ID: 15165822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes infected individuals grouped according to CD4+ cell levels.
    Warren RQ; Wolf H; Zajac RA; Boswell RN; Kanda P; Kennedy RC
    J Clin Immunol; 1991 Jan; 11(1):13-21. PubMed ID: 1708780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immunodeficiency virus type 1 glycoprotein precursor retains a CD4-p56lck complex in the endoplasmic reticulum.
    Crise B; Rose JK
    J Virol; 1992 Apr; 66(4):2296-301. PubMed ID: 1548763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160.
    Hallenberger S; Bosch V; Angliker H; Shaw E; Klenk HD; Garten W
    Nature; 1992 Nov; 360(6402):358-61. PubMed ID: 1360148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of mutations in constant regions 3 and 4 of envelope of simian immunodeficiency virus.
    Morrison HG; Kirchhoff F; Desrosiers RC
    Virology; 1995 Jul; 210(2):448-55. PubMed ID: 7618279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced proteolytic processing of the human immunodeficiency virus type 1 envelope protein in murine Ltk(-) cells.
    Rodriguez D; Rodriguez JR; Esteban M
    AIDS Res Hum Retroviruses; 1995 Jan; 11(1):81-5. PubMed ID: 7734199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment and characterization of human immunodeficiency virus type 1 (HIV-1) envelope-specific CD4+ T lymphocyte lines from HIV-1-seropositive patients.
    Ratto S; Sitz KV; Scherer AM; Manca F; Loomis LD; Cox JH; Redfield RR; Birx DL
    J Infect Dis; 1995 Jun; 171(6):1420-30. PubMed ID: 7769275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular immune response to HIV gp160 vaccine.
    Stricker RB; Goldberg B
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):989. PubMed ID: 7914236
    [No Abstract]   [Full Text] [Related]  

  • 31. Mapping of the human immunodeficiency virus type 2 envelope glycoprotein CD4 binding region and fusion domain with truncated proteins expressed by recombinant vaccinia viruses.
    Otteken A; Voss G; Hunsmann G
    Virology; 1993 May; 194(1):37-43. PubMed ID: 8480426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cytoplasmic tail of HIV-1 gp160 contains regions that associate with cellular membranes.
    Haffar OK; Dowbenko DJ; Berman PW
    Virology; 1991 Jan; 180(1):439-41. PubMed ID: 1984664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy.
    Lin X; Dashti A; Schinazi RF; Tang J
    FASEB J; 1993 Aug; 7(11):1070-80. PubMed ID: 8370478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
    Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycosylation and stability of mature HIV envelope glycoprotein conformation under various conditions.
    Papandreou MJ; Idziorek T; Miquelis R; Fenouillet E
    FEBS Lett; 1996 Jan; 379(2):171-6. PubMed ID: 8635586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein.
    Bergmann C; Stohlmann SA; McMillan M
    Eur J Immunol; 1993 Nov; 23(11):2777-81. PubMed ID: 7693478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Properties of HIV membrane reconstituted from its recombinant gp160 envelope glycoprotein.
    Cornet B; Decroly E; Thines-Sempoux D; Ruysschaert JM; Vandenbranden M
    AIDS Res Hum Retroviruses; 1992 Oct; 8(10):1823-31. PubMed ID: 1457195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of calcium ions on proteolytic processing of HIV-1 gp160 precursor and on cell fusion.
    Moulard M; Montagnier L; Bahraoui E
    FEBS Lett; 1994 Feb; 338(3):281-4. PubMed ID: 8307195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural properties of HIV-1 Env fused with the 14-kDa vaccinia virus envelope protein.
    Rodriguez JR; Rodriguez D; Esteban M
    Virology; 1991 Apr; 181(2):742-8. PubMed ID: 2014647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptional and post-transcriptional mechanisms are involved in the absence of CD4 surface expression in two HIV-1 chronically infected T cell lines.
    Serpente N; Hemar A; Cefai D; Dautry-Varsat A; Fagard R; Fischer S; Vaquero C
    Int Immunol; 1993 Aug; 5(8):939-47. PubMed ID: 8104473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.